Revising the ABIDE MCI to dementia prediction model for automated cerebrospinal fluid assays - PubMed
3 months ago
- #Alzheimer's disease
- #dementia prediction
- #cerebrospinal fluid
- The study revised the ABIDE model to predict progression from mild cognitive impairment (MCI) to dementia using automated cerebrospinal fluid (CSF) biomarker assays.
- A total of 2413 MCI participants from seven observational cohorts were included, with 40% using the Elecsys automated platform.
- During follow-up, 42% of participants developed dementia, with 58% of these being amyloid-positive.
- The refitted ABIDE model showed good discrimination (Harrell's C of 0.70) and calibration, especially in amyloid-positive patients.
- The model aims to support clinical discussions regarding amyloid-targeted therapies (ATTs) for Alzheimer's disease.